Esperion Therapeutics | ESPR - Sales Revenues


Esperion Therapeutics reported $168.45M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Alterity Therapeutics Limited AUD 596.04K 584.66K Dec/2025
Amarin USD 49.22M 451K Dec/2025
Amgen USD 8.62B 1.28B Mar/2026
Biogen USD 2.25B 30M Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Cipla INR 65.41B 9.77B Mar/2026
CSL USD 8.33B 4.79B Dec/2025
Cytokinetics USD 19.35M 1.59M Mar/2026
Daiichi Sankyo JPY 587B 28.89B Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
Geron USD 51.84M 3.82M Mar/2026
Grifols EUR 2B 306.7M Mar/2026
Halozyme Therapeutics USD 377M 74.76M Mar/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Ionis Pharmaceuticals USD 246M 43M Mar/2026
Merck USD 16.29B 110M Mar/2026
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 389M 289M Mar/2026
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Pfizer USD 14.5B 3.08B Mar/2026
PTC Therapeutics USD 273M 108.3M Mar/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Sanofi EUR 11.24B 60M Mar/2026
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
United Therapeutics USD 781.5M 8.7M Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024